Kevin P. Kerns

Array ( [id] => 9777674 [patent_doc_number] => 08852878 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-07 [patent_title] => 'Method for identifying an antagonist of guanine nucleotide releasing factor 1' [patent_app_type] => utility [patent_app_number] => 13/197242 [patent_app_country] => US [patent_app_date] => 2011-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 13341 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13197242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8975967 [patent_doc_number] => 20130209396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/812582 [patent_app_country] => US [patent_app_date] => 2011-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 37668 [patent_no_of_claims] => 70 [patent_no_of_ind_claims] => 34 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13812582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7650831 [patent_doc_number] => 20110300100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-08 [patent_title] => 'IL-11 MUTEINS' [patent_app_type] => utility [patent_app_number] => 13/189850 [patent_app_country] => US [patent_app_date] => 2011-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 12785 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0300/20110300100.pdf [firstpage_image] =>[orig_patent_app_number] => 13189850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7817477 [patent_doc_number] => 20120064097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-15 [patent_title] => 'Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates' [patent_app_type] => utility [patent_app_number] => 13/186925 [patent_app_country] => US [patent_app_date] => 2011-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8937 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20120064097.pdf [firstpage_image] =>[orig_patent_app_number] => 13186925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9112556 [patent_doc_number] => 08568723 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-29 [patent_title] => 'Method of reducing pruritis using IL-31 monoclonal antibodies' [patent_app_type] => utility [patent_app_number] => 13/185130 [patent_app_country] => US [patent_app_date] => 2011-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46724 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13185130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7573531 [patent_doc_number] => 20110269187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-03 [patent_title] => 'High Affinity Human Antibodies to Human IL-18 Receptor' [patent_app_type] => utility [patent_app_number] => 13/184603 [patent_app_country] => US [patent_app_date] => 2011-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9967 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0269/20110269187.pdf [firstpage_image] =>[orig_patent_app_number] => 13184603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8054105 [patent_doc_number] => 20120076797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-29 [patent_title] => 'Modulation of kit signaling and hematopoietic cell development by IL-4 receptor modulation' [patent_app_type] => utility [patent_app_number] => 13/135654 [patent_app_country] => US [patent_app_date] => 2011-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19723 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0076/20120076797.pdf [firstpage_image] =>[orig_patent_app_number] => 13135654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8396343 [patent_doc_number] => RE043672 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2012-09-18 [patent_title] => 'Anti-IL-6 antibodies, compositions, methods and uses' [patent_app_type] => reissue [patent_app_number] => 13/178998 [patent_app_country] => US [patent_app_date] => 2011-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 26 [patent_no_of_words] => 44936 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13178998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8282461 [patent_doc_number] => 08216562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-07-10 [patent_title] => 'Inhibiting non-hematopoietic cancer with interleukin 6' [patent_app_type] => utility [patent_app_number] => 13/176093 [patent_app_country] => US [patent_app_date] => 2011-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 1 [patent_no_of_words] => 4518 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13176093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7712306 [patent_doc_number] => 20120004398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-05 [patent_title] => 'Method for Uses of Protein Precursors as Prodrugs' [patent_app_type] => utility [patent_app_number] => 13/174520 [patent_app_country] => US [patent_app_date] => 2011-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 4166 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13174520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8950088 [patent_doc_number] => 20130195868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-01 [patent_title] => 'TREATING SURFACE OF THE EYE DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/805175 [patent_app_country] => US [patent_app_date] => 2011-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9645 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13805175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9099118 [patent_doc_number] => 08562990 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-22 [patent_title] => 'Method of treating psoriatic arthritis with an IL-6 receptor antibody' [patent_app_type] => utility [patent_app_number] => 13/160800 [patent_app_country] => US [patent_app_date] => 2011-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10480 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13160800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7776275 [patent_doc_number] => 20120039873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-16 [patent_title] => 'ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/156959 [patent_app_country] => US [patent_app_date] => 2011-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 26482 [patent_no_of_claims] => 59 [patent_no_of_ind_claims] => 30 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20120039873.pdf [firstpage_image] =>[orig_patent_app_number] => 13156959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441452 [patent_doc_number] => 20120258069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'RGD-BINDING COMPOUNDS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/156047 [patent_app_country] => US [patent_app_date] => 2011-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 6453 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13156047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7695953 [patent_doc_number] => 20110230637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-22 [patent_title] => 'MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN' [patent_app_type] => utility [patent_app_number] => 13/151126 [patent_app_country] => US [patent_app_date] => 2011-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12846 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0230/20110230637.pdf [firstpage_image] =>[orig_patent_app_number] => 13151126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11798603 [patent_doc_number] => 09539322 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-10 [patent_title] => 'Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody' [patent_app_type] => utility [patent_app_number] => 13/700355 [patent_app_country] => US [patent_app_date] => 2011-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10329 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13700355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10510507 [patent_doc_number] => 09238080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-19 [patent_title] => 'Bi-specific fusion proteins' [patent_app_type] => utility [patent_app_number] => 13/068808 [patent_app_country] => US [patent_app_date] => 2011-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 42 [patent_no_of_words] => 37474 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13068808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8663982 [patent_doc_number] => 08377442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-02-19 [patent_title] => 'Method of treating inflammatory eye disease with IL-1β binding antibodies' [patent_app_type] => utility [patent_app_number] => 13/109680 [patent_app_country] => US [patent_app_date] => 2011-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 22 [patent_no_of_words] => 36189 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13109680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7663632 [patent_doc_number] => 20110312901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-22 [patent_title] => 'METHODS OF INHIBITING CELL DEATH OR INFLAMMATION IN A MAMMAL BY ADMINISTERING A BCL PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/107866 [patent_app_country] => US [patent_app_date] => 2011-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12258 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0312/20110312901.pdf [firstpage_image] =>[orig_patent_app_number] => 13107866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7586363 [patent_doc_number] => 20110280873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-17 [patent_title] => 'MCP1-Ig FUSION VARIANTS' [patent_app_type] => utility [patent_app_number] => 13/105453 [patent_app_country] => US [patent_app_date] => 2011-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12005 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0280/20110280873.pdf [firstpage_image] =>[orig_patent_app_number] => 13105453 [rel_patent_id] =>[rel_patent_doc_number] =>)